- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05169411
Preserving Kidney Function in Children With Chronic Kidney Disease (PRESERVE)
Preserving Kidney Function in Children With Chronic Kidney Disease (PRESERVE)
Pediatric chronic kidney disease (CKD) results from health conditions that reduce kidney function for >3 months. It can progress to end-stage kidney disease (ESKD), which requires dialysis or kidney transplant. In adults, CKD is common and caused mainly by hypertension and diabetes. CKD in childhood is rare and caused primarily by congenital anomalies of the genitourinary system and immune-mediated disorders. The best estimate of pediatric CKD prevalence is <1/15,000 pediatric population. Hypertension occurs in 50% of affected children and is a major risk factor for decline in kidney function. Several clinical practice guidelines have offered recommendations for blood pressure (BP) management in pediatric CKD; however, clinical trial and large-scale observational data are limited, leading to a weak evidence base and substantial practice variation. The purpose of PRESERVE is to provide new knowledge to inform shared decision-making regarding BP management for pediatric CKD. We will leverage the Patient-Centered Outcomes Research network (PCORnet®) infrastructure to conduct large-scale observational studies that will address BP management knowledge gaps for pediatric CKD and sub-groups for whom antihypertensive treatment and outcome associations may be different (e.g., cause of kidney disease and proteinuria).
The project's specific aims are:
Aim 1-Enhance the PCORnet Common Data Model (CDM) for pediatric and rare kidney disease research. We will expand and improve the PCORnet CDM with new pediatric- and kidney-specific variables, study-specific data quality optimization, and linkage with the chronic kidney disease in children (CKiD) cohort study and the US Renal Data System (USRDS). CKiD directly measures kidney function [ie, glomerular filtration rate (GFR)] and includes Ambulatory Blood Pressure Monitoring (ABPM). The USRDS provides complete capture of renal replacement therapy [(RRT) dialysis and transplant], two components of the primary clinical outcome.
Aim 2-Describe and examine the effectiveness of consistent BP and urine protein monitoring for preserving kidney function. We will describe the consistency of BP and urine protein monitoring and will contrast clinic BP assessments with ABPM. In longitudinal analyses, we will evaluate the effects of consistent monitoring of BP and urine protein on kidney function decline.
Aim 3-Compare the effectiveness of BP medication strategies for preserving kidney function. We will compare the effects of (1) BP levels when treatment was started, (2) choice of first-line therapies, and (3) ongoing BP control on kidney function decline. We will also assess adverse events related to hypertension management.
Aim 4-Assess patients' lived experiences related to BP management. We will field a survey that examines patient-centered outcomes by level of BP control and medication management approaches. This Aim will provide information on experiences with BP management from the perspectives of patients, parents, and clinicians that will complement the clinical outcomes studied in Aims 2 and 3.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: PRESERVE Coordinating Center
- Phone Number: 267-426-6917
- Email: preserve@chop.edu
Study Contact Backup
- Name: Jordan Musante, MPH
- Email: musantej@chop.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19103
- Children's Hospital of Philadelphia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Include: patient has an outpatient, ED, or inpatient visit with a physician
- Include: 1 or more eGFR values 30-89 mL/min/1.73m2 using the CKiD U25 formula
- Include: 2 or more eGFR values 30-89 mL/min/1.73m2 on different days using the CKiD U25 formula
- Include: 2 eGFR values in the range 30-89 mL/min/1.73m2 using the CKiD U25 formula greater than or equal to 90 days apart.
Exclusion Criteria:
- Exclude: eGFR value >=90 ml/min using the CKiD U25 formula between the two qualifying eGFRs in mild-moderate range
- Exclude if: Age <1 and >=18 years on CED (see below for definition of CED)
- Exclude if: no nephrologist visit at any time during the study period
- Exclude: if chronic dialysis on or before CED
- Exclude: if kidney transplant on or before CED
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Urine protein dichotomous indicator
We will determine whether urine protein is evaluated at each encounter and create a dichotomous indicator.
|
Evaluating urine protein for children with CKD and hypertension is another guideline recommendation, but the frequency, type of assessment (qualitative or quantitative urine protein), and utility for patients without hypertension are unclear.
We will determine whether urine protein is evaluated at each encounter and create a dichotomous indicator.
|
Active Comparator: angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) categories
The first anti-hypertensive prescribed will be categorized as ACEi, ARB, thiazide diuretic, loop diuretic, beta-blocker, calcium channel blocker, other, and none.
|
The first anti-hypertensive prescribed will be categorized as ACEi, ARB, thiazide diuretic, loop diuretic, beta-blocker, calcium channel blocker, other, and none; secondary analyses will combine ACEi and ARB into a single RAAS blocker category.
We will conduct additional secondary analyses for specific medications with sufficient sample sizes.
|
Active Comparator: Combined renin-angiotensin-aldosterone system (RAAS) blocker category
Secondary analyses will combine ACEi and ARB into a single RAAS blocker category.
|
The first anti-hypertensive prescribed will be categorized as ACEi, ARB, thiazide diuretic, loop diuretic, beta-blocker, calcium channel blocker, other, and none; secondary analyses will combine ACEi and ARB into a single RAAS blocker category.
We will conduct additional secondary analyses for specific medications with sufficient sample sizes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decline in estimated glomerular filtration rate (eGFR)
Time Frame: up to 18 months
|
Time from cohort entrance (defined as day when first estimated glomerular filtration rate will be measured by the following criteria: (1) >50% decline in eGFR, as measured by the U25 formula; (2) eGFR <=15 ml/min as measured by the U25 formula); (3) initiation of chronic dialysis; or (4) kidney transplant. U25 formula: https://doi.org/10.1016/j.kint.2020.10.047 |
up to 18 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Chris Forrest, MD, Children's Hospital of Philadelphia
- Principal Investigator: Michelle Denburg, MD, Children's Hospital of Philadelphia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21-018814
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease Stage 3
-
Guang'anmen Hospital of China Academy of Chinese...Peking University First Hospital; Fangshan Hospital of Traditional Chinese...CompletedStage 4 Chronic Kidney Disease | Stage 3 Chronic Kidney DiseaseChina
-
Zydus Lifesciences LimitedCompletedAnemia | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4India
-
National University, SingaporeUnknownChronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4Singapore
-
Centre Hospitalier Saint Joseph Saint Luc de LyonNot yet recruitingKidney Failure, Chronic | Diet Habit | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 3B | Chronic Kidney Disease, Stage 3 (Moderate) | Chronic Kidney Disease Stage 3A (Disorder)France
-
Fundación de Ayuda a la Investigación sobre la...UnknownChronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4Spain
-
Far Eastern Memorial HospitalActive, not recruitingMetabolic Syndrome | Chronic Disease | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Northwestern UniversityEdward Hines Jr. VA HospitalTerminatedChronic Kidney Disease Stage 3United States
-
Concert PharmaceuticalsCompletedStage 3 Chronic Kidney DiseaseUnited States
-
Seoul National University HospitalCompletedChronic Kidney Disease Stage 3Korea, Republic of
-
University of CopenhagenCompletedChronic Kidney Disease, Stage 3 (Moderate)Denmark
Clinical Trials on Blood pressure
-
Renaissance University Ugbawka, EnuguEnrolling by invitation
-
Meir Medical CenterNovartis PharmaceuticalsTerminatedBlood Pressure, HighIsrael
-
Summit Doppler Systems, Inc.The Cleveland ClinicCompletedPeripheral Arterial DiseaseUnited States
-
University of WashingtonCompleted
-
Kaiser PermanentePatient-Centered Outcomes Research InstituteCompleted
-
Mayo ClinicCompletedHypertension | DiabetesUnited States
-
Mayo ClinicCompletedCoronary Artery IschemiaUnited States
-
Oslo University HospitalRecruitingCardiovascular Diseases | Hypertension | Kidney Transplant; ComplicationsNorway
-
Consorci d'Atenció Primària de Salut de l'EixampleInstituto de Salud Carlos IIICompleted